Alaunos Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 10.05 million compared to USD 9.79 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 0.75 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | +13.79% | +17.86% | +24.47% |
Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.47% | 21.14M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023